Quality agreements between drug companies and the contract manufacturing organizations (CMOs) they employ have been the subject of controversy and FDA scrutiny for many years, prompting the drafting and release of FDA guidance on that topic in 2016. Warning letters and other regulatory actions have resulted from the lack of a quality agreement where one should be in place or poorly written ones that do not ensure the parties have appropriately delineated responsibilities to ensure compliance with GMP regulations.

At the International GMP Conference held virtually in early March 2021 co-sponsored by the University of Georgia at Athens and FDA, Alan Minsk, Partner and Leader of the Food and Drug Practice team at the law firm, Arnall Golden Gregory (AGG), provided a detailed look at quality agreements and his firm’s experience working with clients on the agreements.

[Related: Download a comparison of two of the top CDMOs, that compares GMP enforcement actions, primary citations, and secondary citations.]

CDMO Comparison opt-in


Minsk has been with the AGG for over 20 years and is Leader of the firm’s Food & Drug Practice Team. He focuses his practice on advising pharmaceutical, biologic, medical device, cosmetic, food, and dietary supplement companies on legal and regulatory FDA matters.

A detailed review of his presentation, “Legal and Regulatory Issues Related to Quality Agreements,” is presented in two parts: In Part I, Minsk covers:

  • The content of a quality agreement
  • Why they are important
  • Who should be involved in writing them
  • Dealing with unexpected complications
  • A detailed examination of the FDA guidance and how to comply with it
  • Who has the ultimate responsibility for quality

In Part II, further insights are provided on:

  • Developing a quality agreement
  • Incorporating the basic sections from the FDA guidance
  • Oversight and involvement
  • Impact of the EU privacy regulations
  • Practical issues
  • The importance of using common language
  • Involvement by rank-and-file QA and RA personnel
  • Recommendations made by his firm resulting from work with clients on quality agreements

What is a Quality Agreement?

What is a quality agreement? That term is not found in the Federal Food, Drug, and Cosmetics Act (FD&C Act), or in the implementing regulations. It can be thought of as a contract meeting of the mind.

“You and I decide to agree to do something and hopefully it is going to be in writing,” Minsk explained. “In this case, it is a quality agreement. We are deciding to write down who is going to be responsible for what, specifically delegating responsibilities to ensure compliance with current good manufacturing practices.”

A quality agreement describes specific requirements regarding the product—a drug or biological—and services that are to be provided through specifications. It establishes the roles, responsibilities, and procedures between the parties’ respective regulatory affairs or quality assurance groups.

Why Have a Quality Agreement?

The overall goal is to ensure the quality, safety, and effectiveness of products. A quality agreement aims to minimize—not necessarily eliminate, because that is almost impossible—problems, confusion, errors, and regulatory deficiencies by trying to write down things in advance. That is one of the major goals.

Another reason to have a quality agreement is to make sure that the parties, whether it is internal to an organization or external, are literally and figuratively on the same page and in agreement.

It aims to try to minimize the confusion between the two parties and within the organization, and to try to minimize potential litigation by defining expectations.

A quality agreement describes specific requirements regarding the product

“I have done this for about 28 years in the FDA space,” Minsk said. “You try to allocate and delineate roles and responsibilities and the risks between the parties. The focus is on the specific project at hand, setting timelines for the completion of the specific actions, and writing it down.”

The agreement defines the communication and documentation between the parties. The intent is to reduce the internal frustration of being told what to do without sponsor input and possibly not being able to live up to those expectations. The agreement also tries to anticipate one-offs.

Timing is Important

“As the outside counsel,” Minsk explained, “I focus on the FDA. I have other partners who deal with the corporate side. I look at a lot of quality agreements. I often am brought in, if we are talking about a nine-inning ball game, typically in the eighth inning of the ball game. Sometimes, it is the bottom of the 9th.”

His experience is that often quality and regulatory personnel are brought in in the late innings—maybe the 7th or 8th inning—and yet the commercial team or business development team may have already started the negotiations and almost finalized the agreement. Quality and regulatory are often brought in extremely late, even though they are ultimately responsible for most provisions of the quality agreement.

Those functions may be told that they will be responsible for things like adverse events or out-of-specification investigations—things that may even have deadlines from the FDA perspective.

The agreement defines the communication and documentation between the parties

“They are telling you what you will be doing, and you may be saying, ‘That’s sweet, but you know what? I have my own obligations. I have FDA obligations’,” or even DEA obligations or state obligations, Minsk emphasized.

Quality and regulatory professionals may be frustrated regarding why they were not brought into the process earlier.

“I am the service provider and I am the lawyer,” Minsk commented. “Nobody really cares about my feelings. But you have a certain frustration that you feel about being brought in earlier and that you may even not be able to live up to the expectations, and that is only going to manifest itself when there may be corrective action later or because the company may have product delays, shipment delays or delivery delays, which then, of course, frustrates the entire company.”

Unexpected Complications

When companies sign the quality agreement, “everyone is happy. It is like newlyweds. But then reality sets in, and, inevitably, although no fault of anybody, stuff happens,” Minsk commented.

If you are in QA, you must deal with the “what ifs.” Although the quality agreement is not specifically defined in FDA law, FDA may ask during an inspection to review documents that describe the way the contract service provider was managed or audited.

It is important to understand that changes to the product without proper regulatory approval can make the product violative. For example, if someone changes the product specifications of the drug or biologic, it can make the product an unapproved new drug or biologic.

On the device side, the agency may require a new 510k for the product. If it required a premarket approval application it could become an adulterated product. Or you could make changes that would result in inadequate directions for use or inadequate wording that could also misbrand the product. So, it is important that the agreement attempts to minimize that risk. Not all changes require FDA prior approval.

It is also important to make sure that the agreement is in place before performing GMP activities. “But I am well aware that, often, the agreement is signed ahead of time or the ship has left the dock or whatever the expression may be, and no one wants to be the person in the meeting who raises their hand to say, ‘There may be a problem.’”

Quality and regulatory are often brought in extremely late, even though they are ultimately responsible for most provisions of the quality agreement

Under a quality system, the manufacturer should be sure the contract firm is qualified as the result of due diligence before signing an agreement with the firm.

The contract firm’s personnel should be adequately trained and monitored for performance according to the quality system. Make sure that everyone is on the same page. If the CMO is making a product for the company according to its specs, “it is nice to think that you have your own quality systems or our own GMP SOPs. But this is your product, and the contract firms and contract manufacturer’s quality systems should not conflict,” Minsk emphasized.

The quality agreement should be specific to particular products. One size does not fit all. Often, companies will ask for a template agreement, or companies will often have their own template agreement, Minks said. It is fine to start with that, but you do not finish with a template agreement. While it does help with cost efficiencies, there is no reason to reinvent the wheel. Every project is different.

FDA Guidance

The 2016 FDA guidance on contract manufacturing agreements for drugs is limited to human, veterinary, and biologic drug products. Even though it is specific to drugs, biologics, and veterinary drugs, others, including device manufacturers, can refer to it for guidance and best practice.

The guidance attempts to offer recommendations to industry to minimize quality surprises and to maximize regulatory compliance by building quality into the process early on. That was one of the things FDA talked about a few years ago—trying to be less reactive and fixing the problem at the end, to building compliance into the process earlier.

FDA’s final guidance applies to contract facilities, including analytical testing labs, which package, hold, label, test, or operate any part of the manufacturing process for active pharmaceutical ingredients, drug substances, in process materials, finished drug products, combination products, drug constituents of combination of drug/device products, and biologic drug products.

Commercial manufacturing is covered by the guidance. It does not cover research and development activities, manufacturing of materials for investigational new drug studies, or manufacturing of material for veterinary investigational drugs. However, many of the principles described in the guidance can be applied in precommercial stages of the pharmaceutical life cycle.

Content of the Quality Agreement

Minsk shared a part of the FDA quality agreements guideline that provided key points he felt were important to reinforce (Figure 1).

Figure 1 FDA Quality Agreement Guidance
FIGURE 1 | FDA Quality Agreement Guidance

Note the language in the second part of the first paragraph, “Representatives from each party’s quality unit and other relative stakeholders should participate actively in the drafting of quality agreements.”

Also note that the quality agreement should be separate or at least severable—separated—from the commercial contract, such as a services agreement or a supply agreement. As mentioned previously, the quality agreement may be reviewed by FDA during an inspection.

FDA recommends the quality agreement should include the following provisions:

  • The purpose or the scope, which explains the contract manufacturing services to be provided
  • The definitions, which would provide the precise meaning of terms in the quality agreement
  • Resolution of disagreements or conflict, which would explain how the parties will dissolve the disagreements about product quality issues or other problems; “That one is very important because it determines who has the final say,” Minsk stressed
  • Manufacturing activities, which would document quality unit and other activities related to production processes, quality equipment, facilities and equipment, materials management, change controls, etc.
  • Manufacturing activities, which would document quality unit and other activities related to production processes, quality equipment, facilities and equipment, materials management, change controls, etc.; Described in detail here are all of FDA’s inclusions
  • Lifecycle of and revisions to the quality agreement
  • Documents to describe how parties will communicate information on traceability and prevention of cross-contamination in cases where the contracting manufacturing organization manufactures several different products
  • How the contractor will report manufacturing deviations in drug manufacturing and how deviations will be investigated and resolved under CGMP requirements

The AGG attorney explained an issue he has seen with wording such as, “You will report promptly, as soon as possible, or as soon as practical.” He asked, “What does that mean? Is this biblically promptly or business promptly? I do not know what that means. Your promptly and my promptly are two different things. I think you need to be extremely specific.”

There could be regulatory implications. If you have an obligation to report to FDA within seven days, three days, or 15 days, whatever the issue is, and if there is a regulatory reporting obligation, and all the contract says is, “promptly,” timing of the communication may not fulfill the reporting mandate.

Your corporate counsel may not have been aware of that, and that is not a slight to the corporate counsel, he pointed out. They just may not have been aware that there was a regulatory obligation. That is where you must raise your hand and say, “Excuse me. There may be a regulatory reporting obligation that we have or that they have.” Probably you because you are the one who has the application. “We need to build in some time. We need to decide so we may need 24 hours or 48 hours. Therefore, we need to work backward.”

Expectations for reviewing and approving the documents, including SOPs and manufacturing records by the product owner and the CMO should be included. The quality agreement should be independent of all other business documents because the agreement should focus only on quality and compliance, not business or commercial issues.

Who Has Ultimate Responsibility?

FDA reiterates in the guidance through two hypothetical scenarios that the owners and the contracting facilities are both responsible for current GMP and regulatory compliance. A quality agreement does not exempt the parties from statutory or regulatory responsibilities. That said, the application holder remains ultimately responsible for ensuring that its products are made in compliance with CGMPs or Quality System Regulations (QSRs), even if the quality agreement delegates certain manufacturing activities at the contract facility.

If FDA finds problems at a contract facility, the regulators might determine that it is appropriate to inspect the owner, and owners could be in violation of CGMPs in their servicing of the contract facility’s manufacturing activities.

FDA reminds industry that quality agreements should be available for agency review when the agency conducts establishment inspections. FDA routinely requests to produce evidence of quality agreement or lack thereof.

Examples of FDA enforcement have occurred when a quality agreement was not followed or a problem arose because there was no agreement in place and gaps arose.

Minsk explained that the language the agency generally uses is not always direct.

“It was not that FDA said, ‘You violated GMP for lack of a quality agreement. It is not that black and white. What FDA will say is, ‘There was a violation of law. And if you had a quality agreement, that might not have occurred.’ Or ‘you had a quality agreement, and you did not follow it.’ Or FDA might cite a company for failing to have an effective QC unit if the product’s quality was negatively affected.”

Resource Link

FDA 2016 Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements

[Related: Download a comparison of two of the top CDMOs that compares GMP enforcement actions, primary citations, and secondary citations.]

CDMO Comparison opt-in

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

June 29, 1:30 p.m. EST

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.